The role of the nuclear hormone receptor peroxisome proliferator-activated receptor b/d (PPARb/d) in carcinogenesis is controversial because conflicting studies indicate that it both inhibits and promotes tumorigenesis. In this review, we focus on recent studies on PPARb/d including the significance of increased or decreased PPARb/d expression in cancers; a range of opposing mechanisms describing how PPARb/d agonists, antagonists, and inverse agonists regulate tumorigenesis and/or whether there may be cell context-specific mechanisms; and whether activating or inhibiting PPARb/d is feasible for cancer chemoprevention and/or therapy. Research questions that need to be addressed are highlighted to establish whether PPARb/d can be effectively targeted for cancer chemoprevention.
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The Complexity and Controversial Role of PPARb/d in Carcinogenesis
There is great heterogeneity in the factors required for cancers to develop, grow, and metastasize, from multiple mutations and genetic instability in critical genes, to alterations in 'hallmark' signal transduction checkpoints, that collectively drive proliferation of genetically altered cells into cancerous lesions [1] [2] [3] . This heterogeneity dictates that discovering new and improved approaches for cancer chemoprevention and treatment requires the targeting of pivotal gene products whose function directly drives cancer. Given these caveats, the focus of this review is on the nodal transcription factor, PPARb/d (see Glossary), which may have important regulatory effects on hallmark checkpoints. Several recent reviews have summarized the controversial nature of PPARb/d in cancer [4] [5] [6] [7] [8] . Thus, the primary focus of this review is to critique recent studies that have influenced this field over the past 5 years.
To frame this review, we briefly outline the first study to report a relation between PPARb/d and cancer. This was based on observations made in a cohort of four human colon cancer tumors showing higher expression of PPARb/d compared with control tissue [9] . The mechanism hypothesized to mediate increased PPARb/d expression was that mutations of the gene encoding the protein adenomatous polyposis coli (APC) in colon tumors led to increased b-Catenin/T cell factor 4 (TCF4) signaling, causing increased transcription of the Cyclin D1 (CCND1), MYC, and PPARD genes, which collectively increased the net proliferation of mutant cancer cells. This study led to a hypothesis that putatively explained how inhibitors of Cyclooxygenase 2 (COX2), a key enzyme involved in the production of prostaglandins, prevented cancer: inhibition of COX2 decreased the production of endogenous PPARb/d agonists, causing increased expression of yet-to-be identified target genes that, combined with expression of CCND1 and MYC, causes the net proliferation of cancerous cells. However, to date, both this putative APC-driven mechanism of PPARb/d regulation and the targeting of this receptor by inhibiting COX2 metabolites remain uncertain (reviewed in [4] [5] [6] [7] [8] ).
Trends
PPARb/d expression in cancers requires careful quantification and validation.
Given that PPARb/d is constitutively high expressed and regulates multiple pathways involved in carcinogenesis, and natural and synthetic agonists, antagonists, and inverse agonists already exist, it has great potential as a target for cancer chemoprevention. 
Limitations in Measuring PPARb/d Expression Levels
By contrast, higher expression of PPARb/d protein and/or PPARD mRNA has also been reported in other cancers besides colon, where mutations in critical oncogenic genes in addition to APC are more closely correlated with the mutation 'signature' genotype required for carcinogenesis [2] . Given that mutations in APC are primarily associated with colon cancer, this lack of concordance may not be surprising. Whether genes such as Tumor protein P53 (TP53), KRAS, Epidermal growth factor receptor (EGFR), Phosphatidylinositol 3-kinase (PI3KCA), Phosphatase and tensin homolog (PTEN), and others influence PPARb/d expression and/or function has not been critically examined to date. [4] [5] [6] [7] [8] ). Recent studies using colon-specific Ppard-null or transgenic mice that were treated with the colon cancer carcinogen azoxymethane either in combination with dextran sodium sulfate (DSS), or alone have also provided conflicting results. Colon-specific disruption of Ppard caused no change in colon tumor multiplicity following administration of azoxymethane and DSS [14] . By contrast, disruption of PPARb/d mitigated azoxymethaneinduced colon tumor multiplicity, compared with controls [15] . Furthermore, enhanced colon-specific expression of PPARb/d caused an increase in colon tumor multiplicity following administration of azoxymethane and DSS [16] . Consistent with the latter observation, overexpression of PPARb/d in colon caused a dose-dependent increase in azoxymethane-induced colon carcinogenesis in two different FVB/N mouse lines, and overcame the relative resistance to azoxymethane-induced colon carcinogenesis in C57BL/6 mice compared with controls, [17] . While the findings from these four studies from two laboratories are difficult to reconcile, the lack of changes in tumor multiplicity in the one model [14] could reflect the requirement of PPARb/d to either inhibit or promote tumorigenesis by cells in the tumor microenvironment, such as tumor stromal cells, fibroblasts, macrophages, and so on. Thus, it is somewhat counterintuitive that overexpression of PPARb/d in the colon caused enhanced tumorigenesis, because recent evidence from three laboratories and database searches indicate that PPARb/d expression is highly constitutively expressed in this tissue, in both humans and mice [13, 18, 19] . It remains a possibility that unidentified endogenous PPARb/d agonists or antagonists exist that modulate these effects, that the gut microbiome influenced these study results, or that the phenotype is altered by disruption of a gene or genes by the recombinant transgene. Further studies are needed to examine these ideas.
The Role of PPARb/d in Human Cancer Cell Lines Similar to the recent studies examining the role of PPARb/d in mouse colon cancer models, examination of the role of this receptor in human cancer cell lines have also been difficult to interpret. Consistent with the notion that relatively higher expression of PPARb/d inhibits tumorigenesis, the growth and proliferative indices of a human colon cancer cell line and of ectopic xenografts in immune-compromised mice developing from a derivative of this cell line expressing an RNAi against PPARb/d, were markedly increased compared with controls [20] . This effect may have been due to reduced differentiation and increased expression of vascular endothelial growth factor (VEGF) [20] . These experiments are consistent with studies showing that overexpression of PPARb/d and ligand activation of PPARb/d markedly inhibited ectopic xenografts using both estrogen receptor (ER)+ and ER-human breast cancer cell lines, in an immune-compromised mouse model [21] . These results suggest that expression of PPARb/d inhibits hallmark cancer checkpoints, such as prevention of sustained cell growth, by promoting terminal differentiation and inhibiting angiogenesis. By contrast, knockdown of PPARb/d in both ER+ and ER-human breast cancer cells inhibited proliferation in vitro [22] . These opposing results are somewhat striking, since previous studies suggested that only ER + breast cancer cells were sensitive to the growth stimulatory effects of a PPARb/d ligand [23] . This hypothesis is contradicted by studies showing that knocking down PPARb/d inhibits growth in both ER+ and ER-human breast cancer cells [22] , and that inhibition of tumorigenicity is observed in ER+ and ER-human breast cancer cells when PPARb/d is overexpressed [21] . 
Differential and Opposing Role for PPARb/d in Tumor Progression
Despite attempts using new approaches to determine whether expression of PPARb/d promotes or inhibits cancer using both mouse and human models, this issue remains unclear. This is of interest given the known expression patterns for PPARb/d in various tissues and cancers, with the former typically exhibiting relatively high expression and the latter exhibiting relatively low expression [13, 18, 19, 24] . Moreover, there is also evidence in some models that PPARb/d is found primarily in the nucleus, where it is constitutively active, as revealed by chromatin binding and both repression and activation of several target genes [25, 26] . These data are in line with the view that the relatively high expression of PPARb/d has a functional role in normal tissues, and argues for an antitumorigenic role for this receptor. However, if an endogenous PPARb/d antagonist and/or inverse agonist does exist, this could also indicate a protumorigenic role for PPARb/d. The relative activity and biological effects of PPARb/d following binding to agonists, antagonists, and/or inverse agonists (Box 1), and whether the target gene(s) are tumor suppressor or oncogenic in nature, is another area that is related to relative expression levels.
Public expression databases provide a useful tool to identify possible associations of specific genes with the clinical course of cancers. Analyses of microarray databases identified significant associations between expression of PPARD and its target gene ANGPTL4 (encoding angiopoietin-like 4 protein) with the relapse-free survival of patients with cancer ( Figure 1 based on a correlative survival analysis using large microarray databases that PPARb/d has suppressive and/or protumorigenic roles in human cancer. This is based on comparing relative PPARD mRNA in tumors and normal tissue from patients with different clinical outcomes. This is illustrated here using analyses of databases as described previously [58] [59] [60] .
(A) Relapse-free survival (RFS) in different cancers is associated with the relative expression of PPARD or ANGPTL4 mRNAs. Note that there is a significant association between the relative expression of PPARD and ANGPTL4 mRNAs and RFS in lung (combined adenocarcinoma and squamous carcinoma), gastric, breast, and serous ovarian cancer, but it can be increased (red bars) or decreased (blue bars). (B) Kaplan-Meier analysis illustrating an association between the relative expression of PPARD or ANGPTL4 mRNAs and the RFS of patients with lung adenocarcinoma (i,ii). By contrast, KaplanMeier analysis indicates that, while higher expression of PPARD mRNA in patients with breast cancer is associated with longer RFS compared with patients with breast cancer with lower expression of PPARD mRNA, the inverse association is observed between patients with breast cancer and relative expression of ANGPTL4 mRNA (iii,iv). However, associations between relative mRNA expression of PPARD mRNA does not necessarily account for the effects of endogenous or exogenous agonists, antagonists, or inverse agonists. Furthermore, this approach is only correlative because survival analyses using data from public databases (including The Cancer Genome Atlas Network) of mRNA analysis have significant limitations (discussed in the main text). This illustrates the need for more comprehensive analyses, as outlined in this review.
correlations clearly support a differential and probably opposing role for PPARb/d in tumor progression.
Modulating Hallmarks and Enabling Characteristics of Cancer by PPARb/d
While the expression of PPARb/d is required for this receptor to modulate cellular processes including cancer, an endogenous or exogenous agonist, antagonist, or inverse agonist is also necessary to activate or inhibit this transcription factor. Given the relatively high intracellular concentration of lipids and lipid metabolites (i.e., fatty acids, etc.) that can act as PPARb/d agonists [27, 28] , antagonists, or inverse agonists, the proportion of PPARb/d that is bound with these compounds is likely high. This is consistent with the finding that apo-PPARb/d was not observed in the crystal structure as originally reported [29] , due to the presence of fatty acids later found to occupy the ligand-binding domain of PPARb/d [30] . Thus, it is not surprising that PPARb/d is found primarily in the nucleus in most tissues bound with its obligatory heterodimerization partner retinoic X receptor (RXR) [18] , and is constitutively repressing and/or activating the expression of a subset of target genes [25, 26] . However, the dynamic intracellular activity of PPARb/d can vary significantly based on numerous variables, including the relative expression and localization of the receptor, relative expression of co-effector proteins, the relative concentrations of endogenous or exogenous agonists, antagonists, or inverse agonists, and the relative proximity to binding sites on chromatin of regulatory regions of target genes [31] [32] [33] . Given the complex regulatory pathways that can influence PPARb/d, it is not surprising that there is a range of effects attributed to the modulation of PPARb/d that may mediate effects that influence cancer.
Impact of PPARb/d Activation on the Hallmarks of Cancer
There are six well-accepted hallmarks of cancer (resisting programmed cell death, sustaining proliferative signaling, evading growth suppressors, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis), two emerging hallmarks of cancer (deregulating cellular energetics and avoiding immune destruction), and two enabling characteristics of cancer (genomic instability and mutation, and tumor-promoting inflammation) [1] . Ligand activation of PPARb/d or modulating the activity of PPARb/d using antagonists or inverse agonists may alter some of these hallmarks enabling full-scale carcinogenesis (Figure 2 ). However, results from these studies (Table 1 ) remain conflicting because they indicate that PPARb/d either inhibits or promotes tumorigenesis by modulating these hallmarks and enabling characteristics of cancer. In addition to Table 1 , the reader is encouraged to examine other recent reviews that contrast in vivo and in vitro studies describing the effects of PPARb/d, and PPARb/d agonists and antagonists in many cancer models [4] [5] [6] [7] . By contrast, there is strong evidence that ligand activation of PPARb/d can induce terminal differentiation, which is known to reverse sustained cell proliferation and promote sensitivity to growth suppressors (reviewed in [4] [5] [6] [7] [8] ). Furthermore, there is a large body of evidence demonstrating that PPARb/d inhibits innate immune signaling, which may prevent tumor-promoting inflammation (reviewed in [4] [5] [6] [7] [8] ), an enabling characteristic of cancer [1] .
One of the first studies describing a role for PPARb/d in promoting resistance to cell death, sustaining proliferative signaling and evasion of growth suppressors, used somatic cells that resembled primary mouse keratinocytes [34] . The proposed hypothesis postulated that PPARb/ d directly upregulated expression of 3-phosphoinositide-dependent protein kinase-1 (PDPK1) and integrin-linked kinase (ILK) and downregulated PTEN, leading to increased phosphorylation of AKT1 and inhibition of apoptotic signaling [34] . Subsequent studies supported this hypothetical pathway in cancer models, while others did not (reviewed in [4] [5] [6] [7] [8] ). In particular, studies using confirmed mouse primary keratinocytes, mouse skin, and numerous cancer models showed no changes in the expression of these proteins and/or activity of this pathway (reviewed in [4] [5] [6] [7] [8] Included shRNA controls to demonstrate specificity [73] many putative PPARb/d target genes, including PDPK1 in primary keratinocytes, and no evidence of promoter occupancy of PPARb/d on or near these putative target genes was observed in the same model [26] . Indeed, other recent studies indicate that PPARb/d represses PDPK1, ILK, and phosphorylation of AKT1 in oncogenic keratinocytes [35] . One possible explanation for these data suggesting that ligand activation of PPARb/d promotes antiapoptotic activity is provided by a recent study showing that markers of early apoptosis are dosedependently decreased in a human colon cancer cell line (DLD1) following co-exposure to hydrogen peroxide, but this change is in fact associated with a decrease (not an increase) in viable cells, and a marked increase in late apoptotic and/or necrotic cells compared with controls [24] . This illustrates the need for future studies to include a thorough assessment of apoptosis to unravel the precise function of PPARb/d in this context. An ancillary hypothesis that all transretinoic acid (atRA), an agonist of RAR, can be differentially shuttled to activate PPARb/d rather than RAR, based on a relatively high ratio of intracellular cellular retinoic acid-binding protein II (CRABPII) to fatty acid-binding protein (FABP5) to promote PPARb/d-dependent antiapoptotic activity has also been postulated, but is not strongly supported by other studies, as previously discussed in detail (reviewed in [4] [5] [6] [7] [8] ). This pathway is based on the hypothesis that the relative expression of FABP5 and CRABPII is different [36] , but this putative difference has not been accurately quantified to date in any cell type. Moreover, the notion that breast cancer cells with higher FABP5 expression may be more sensitive to the chemopreventive activities of atRA [37] , based on studies in a human keratinocyte cell line [36] , is not supported by the finding that the relative expression of FABP5 protein is either not detected or is negligibly expressed in human breast cancer tissue, compared with nontransformed tissue [13] .
Induction of angiogenesis is another hallmark of cancer and studies suggest that modulation of PPARb/d activity influences this process. VEGF and ANGPTL4 are two proteins that can affect angiogenesis and there are opposing studies showing that PPARb/d affects VEGF, ANGPTL4, and angiogenesis in cancer models (Box 2). However, there is currently no consensus on how PPARb/ d influences angiogenesis (reviewed in [4] [5] [6] [7] [8] ). Two recent studies suggest that PPARb/d agonists increase expression of VEGF mRNA modestly in cancer cells, but these studies did not measure angiogenic endpoints, and the effects were independent of PPARb/d and, therefore, likely due to off-target effects of the agonists used (GW501516 and L165041) [38, 39] . By contrast, secretion of VEGF was increased in a human colon cancer cell line by knockdown of PPARb/d, and ligand
Box 2. Conflicting Roles of ANGPTL4 in Cancer
Secreted ANGPTL4 is cleaved by extracellular proteases into biologically active N-terminal (nANGPTL4) and C-terminal (cANGPTL4) fragments circulating through the blood stream [74] . Whereas a major function of nANGPTL4 is inhibition of lipoprotein lipase, cANGPTL4 has role in tumor progression and metastasis [75] [76] [77] . Thus, ANGPTL4 enhances cell migration [78, 79] , cancer cell invasion [49] , and angiogenesis [80] . ANGPTL4 also inhibits anoikis of circulating tumor cells [81] and increases the permeability of lung capillaries to promote their extravasation [78, 82] , thereby promoting metastasis formation. This is consistent with the presence of ANGPTL4 in gene expression signatures indicative of metastasis and poor outcomes in humans [83] and the correlation of ANGPTL4 protein expression with venous invasion of gastric and colon carcinoma cells [44, 45] . Therefore, it is not surprising that multiple oncogenic signaling pathways regulate the ANGPTL4 gene, including hypoxia [84] , activator protein 1 (AP1) [85] , and transforming growth factor beta (TGFb) [79, 85] .
By contrast, an inhibitory role for ANGPTL4 in angiogenesis has also been described, although in this system inhibition of migration is linked to diminished chemotaxis and decreased cell proliferation [86] . There is also a conflicting report suggesting an inhibitory role for ANGPTL4 in two mouse models that examined cell migration [46] . However, some of these data were not reproduced in other studies using different assays [49] . This discrepancy may be due to differences in the specific experimental approach used; Galaup and colleagues [46] used transfected cells overexpressing ANGPTL4, whereas Adhikary et al. used soluble recombinant protein [49] , because the relation between the processing of ANGPTL4 and its different biological functions is poorly understood. It can also not be ruled out that different signaling mechanisms are involved, as suggested by studies using soluble [87] or matrix-bound ANGPTL4 [88] . Furthermore, the mouse Angptl4 gene lacks functional SMAD-binding sites and, consequently, is not inducible by TGFb [89] , which may cause species differences in the role of ANGPTL4 in angiogenesis.
activation of PPARb/d inhibited secretion of VEGF, an effect that was mitigated by knockdown of PPARb/d [20] . Examination of human umbilical vein endothelial cells (HUVEC) cells revealed that L165041 also inhibits VEGF protein expression, tube formation, HUVEC proliferation and migration, and angiogenesis in vivo [40, 41] . However, the decrease in VEGF secretion and HUVEC migration were not mediated by PPARb/d in one study [41] . While it is not clear that VEGF is a bona fide PPARb/d target gene, there is strong evidence that ANGPTL4 is directly regulated by ligand activation of PPARb/d, and also by PPAR/ and PPARg [42] . While some studies indicate that ANGPTL4 promotes tumorigenesis [43] [44] [45] , other studies suggest that ANGPTL4 inhibits angiogenesis and tumorigenesis [46] [47] [48] (Box 2). A similarly disparate picture emerged for associations between PPARD and ANGPTL4 mRNA expression and the clinical outcome of different cancers ( Figure 2 ). Since all three PPARs can increase expression of ANGPTL4 [42] and PPAR/ and PPARg agonists are currently being investigated as chemopreventive agents in humans (reviewed in [4] [5] [6] [7] [8] ), it will be important to determine how ANGPTL4 influences cancer in response to changes in expression by PPARb/d agonists ( Figure 1 ).
An elegant study recently provided some novel insight that may explain this phenomenon. In MDA-MB-231 human breast cancer cells, ANGPTL4 among all the genes examined exhibited the largest increase in response to a PPARb/d agonist, and two inverse PPARb/d agonists markedly decreased expression of ANGPTL4 [49] . This change in ANGPTL4 mRNA and ANGPTL4 protein expression by inverse PPARb/d agonism was associated with inhibition of MDA-MB-231 cell invasion, suggesting that inverse agonists provide a suitable tool for interfering with cancer growth and progression. Surprisingly, MDA-MB-231 cell invasion was not enhanced by PPARb/d agonists, suggesting that the high expression of ANGPTL4 in these cells triggers invasion without the need for exogenous PPARb/d agonists [49] . However, it is important to note that there is considerable complexity associated with this type of effect and likely reflects different interactions between PPARb/d and endogenous agonists, antagonists, and/or inverse agonists. That PPARb/d inverse agonism provides a new approach to prevent cell invasion, a hallmark of cancer associated with metastasis, is also supported by another recent study demonstrating that TAMs from human serous ovarian carcinoma ascites exhibit marked expression of ANGPTL4 and other genes associated with cancer, presumably due to the high concentration of endogenous polyunsaturated fatty acids that act as PPARb/d agonists [28] . Interestingly, PPARb/d agonists have little influence on TAM gene expression, likely due to the occupancy of endogenous fatty acids, while inverse agonists caused a decrease in ANGPTL4 and other genes associated with cancer [28] . Understanding the role of PPARb/d in tumorigenesis is further complicated by its potential role in host cells of the tumor microenvironment. Independent studies have shown a defect in tumor vascularization in Ppard-null mice [50, 51] , and the publication discussed above reported the deregulation of potentially pro-tumorigenic PPARb/d target genes in TAMs of patients with ovarian cancer [28] . In addition, recent findings suggest that PPARb/d agonists influence VEGF expression through a mechanism that is not mediated by PPARb/d, and PPARb/d-dependent downregulation of VEGF in cancer models can be observed. Collectively, there is increasing evidence that inverse agonists of PPARb/d may be suitable for targeting cancer cell invasion, which may inhibit this hallmark of cancer.
By contrast, PPARb/d has anti-inflammatory activities, suggesting that this receptor should be associated with anticarcinogenic effects (reviewed in [4] [5] [6] [7] [8] ). Intriguingly, a recent study contradicts a much larger body of evidence because it suggests that PPARb/d promotes proinflammatory signaling and tumor progression in a mouse model of colon cancer [52] . One possible explanation for this counterintuitive finding is that the activation of PPARb/d in macrophages is associated with strong anti-inflammatory gene expression and functional 'signature', but surprisingly, activation of PPARb/d in macrophages was also associated with a modest immune stimulatory component [53] . This striking observation suggests that there could be cell context-specific function involving immune cells and inflammation that could influence tumorigenesis in an undetermined way. Further studies are needed to address this hypothesis, because immune suppression and inhibition of inflammation are two hallmarks of cancer that could be modulated by PPARb/d.
Several recent studies have revealed a novel mechanism by which ligand activation of PPARb/d inhibits non-melanoma skin tumorigenesis by modulation of cell cycle progression and senescence. In mouse keratinocytes expressing an oncogenic form of Harvey sarcoma ras (HRAS), ligand activation of PPARb/d can cause binding to the retinoblastoma protein family members p130 or p107, leading to G2/M arrest of the cell cycle [54] . In mouse keratinocytes expressing an oncogenic form of HRAS, ligand activation of PPARb/d can promote oncogene-induced senescence by repressing expression of PDPK1 and ILK, causing increased phosphorylation of ERK and decreased phosphorylation of AKT1 [35] . This collectively increases p53/p27, causing enhanced cellular senescence and inhibition of HRAS-dependent tumorigenesis [35] . Interestingly, higher expression of PPARb/d also correlates with increased cellular senescence in human benign neurofibromas and colon adenomas [35] . Moreover, this increase in oncogene-induced senescence appears to be mediated in part by PPARb/d-dependent repression of endoplasmic reticulum stress [55] .
While there are many studies demonstrating that PPARb/d protects against oncogene-induced skin tumorigenesis (reviewed in [4] [5] [6] [7] [8] ), there is a recent study suggesting that antagonizing PPARb/d inhibits ultraviolet-induced skin tumorigenesis, by activating the SRC pathway [56] . However, this study applied the PPARb/d antagonist before exposure to ultraviolet radiation. Since the PPARb/d antagonist used for this work (GSK0660) absorbs ultraviolet light with great efficacy, it cannot be ruled out that the observed antitumor activity was due to a sunscreen effect. Collectively, the studies summarized above provide strong evidence that PPARb/d can modulate cell cycle progression and senescence in non-melanoma skin cancer, two mechanisms that are central to the hallmarks of cancer.
Concluding Remarks and Future Perspectives
It is now known that constitutive expression of PPARb/d is high in many tissues, including the gut epithelium and keratinocytes, and that it is typically found in the nucleus, where it functions to repress or activate target gene expression. Given this relatively high expression and the fact that this transcription factor controls multiple genes, PPARb/d remains a viable molecular target for cancer chemoprevention (see Outstanding Questions). Whether this will be accomplished by using natural or synthetic agonists, antagonists, or inverse agonists remains to be determined. Since there is no known evidence that these chemicals are genotoxic, it is likely that effective targeting of PPARb/d will result in modulation of one or more molecular pathways involved in the hallmarks of cancer. Corroborating PPARb/d-dependent pathways suitable for new approaches for cancer chemoprevention and/or chemotherapy would likely be most effectively completed by cooperative collaborations between laboratories that have published opposing results. This type of approach may also be suitable for many other areas of controversy in cancer biology. 
